Monte Rosa Therapeutics (GLUE) Total Current Liabilities (2023 - 2025)
Historic Total Current Liabilities for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $61.4 million.
- Monte Rosa Therapeutics' Total Current Liabilities rose 4755.41% to $61.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.4 million, marking a year-over-year increase of 4755.41%. This contributed to the annual value of $156.9 million for FY2024, which is 23685.18% up from last year.
- Monte Rosa Therapeutics' Total Current Liabilities amounted to $61.4 million in Q3 2025, which was up 4755.41% from $41.9 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Total Current Liabilities ranged from a high of $156.9 million in Q4 2024 and a low of $19.1 million during Q2 2023
- Over the past 3 years, Monte Rosa Therapeutics' median Total Current Liabilities value was $41.9 million (recorded in 2025), while the average stood at $50.3 million.
- In the last 5 years, Monte Rosa Therapeutics' Total Current Liabilities soared by 23685.18% in 2024 and then plummeted by 117.12% in 2025.
- Over the past 3 years, Monte Rosa Therapeutics' Total Current Liabilities (Quarter) stood at $46.6 million in 2023, then surged by 236.85% to $156.9 million in 2024, then plummeted by 60.85% to $61.4 million in 2025.
- Its Total Current Liabilities was $61.4 million in Q3 2025, compared to $41.9 million in Q2 2025 and $59.2 million in Q1 2025.